Quick answers
- What is Liraglutide used for?
- The FDA-approved label (Victoza, Novo Nordisk, October 14, 2025) says: “VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Liraglutide have a boxed warning?
- Yes. The FDA label for Victoza has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Liraglutide?
- The FDA drug shortage list shows “Current shortage” for a product of this medicine (updated October 14, 2026). Ask your pharmacist about alternatives.
- Has Liraglutide been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started April 24, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Liraglutide?
- 13 companies list prescription products of Liraglutide in the FDA NDC Directory, including A-S Medication Solutions, Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) and Orbicular Pharmaceutical Technologies Private Limited.
What Liraglutide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use …
— FDA label: Victoza, Novo Nordisk, effective October 14, 2025. Read the full label on DailyMed →
The FDA has 18 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
15 of 18 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| liraglutide 6 mg/mL injection | Generic | $28.58–$29.19 per mL 12 packages, lowest to highest |
| liraglutide 6 mg/mL injection | Brand: Victoza | $87.75–$87.76 per mL 2 packages, lowest to highest |
| liraglutide 6 mg/mL injection, solution | Generic | $28.58–$47.27 per mL 5 packages, lowest to highest |
| liraglutide 6 mg/mL injection, solution | Brand: Saxenda | $87.04 per mL |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions5 products
- Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)3 products
- Orbicular Pharmaceutical Technologies Private Limited2 products
- Cipla USA Inc.2 products
- Biocon Pharma Inc.2 products
- Teva Pharmaceuticals, Inc.1 product
- Lupin Pharmaceuticals, Inc.1 product
- Novo Nordisk Pharmaceutical Industries, LP1 product
- Meitheal Pharmaceuticals Inc.1 product
- Novo Nordisk1 product
- Teva Pharmaceuticals USA, Inc.1 product
- Hikma Pharmaceuticals USA Inc.1 product
- NorthStar Rx LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022341 VICTOZA | Novo Nordisk Inc | January 25, 2010 | 28, latest October 14, 2025 2025: Labeling · 2025: Labeling · 2025: Labeling |
| NDA206321 SAXENDA | Novo | December 23, 2014 | 19, latest June 2, 2026 2026: Labeling · 2026: Labeling · 2025: Labeling |
Generic approvals (8)
- ANDA215503Hikma · December 23, 2024
- ANDA218115Emerge Bioscience · April 2, 2025
- ANDA215421Lupin · July 22, 2025
- ANDA214568Teva Pharms · August 27, 2025
- ANDA217590Orbicular · January 14, 2026
- ANDA217063Biocon Pharma · February 24, 2026
- ANDA217234Orbicular · February 24, 2026
- ANDA215245Biocon Pharma · March 11, 2026
Shortage status
Current shortage · updated October 14, 2026 · first posted July 18, 2023
| Product | Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) |
|---|---|
| Availability | Available |
| Company | Hikma Pharmaceuticals USA, Inc. |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
April 24, 2026 · Class II · Ongoing · D-0541-2026
Presence of particulate matter: a white thread-like structure in the cartridge
Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70 — Lupin Pharmaceuticals Inc.
-
March 22, 2021 · Class II · Terminated · D-0622-2021
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
ViCTOZA (liraglutide) injection, 18 mg/3 mL (6 mg/mL), contains: 1 Victoza Pen, Sample Not for Resale, Rx only, Manufactured by: Novo Nordisk A/S, Bagesvaerd, Denmark NDC 0169-4060-90 (Pen), 0169-4060-99 (Kit) — Novo Nordisk Inc
-
March 22, 2021 · Class II · Terminated · D-0618-2021
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Saxenda (liraglutide) Injection, 18 mg/3 mL (6 mg/mL), 1 x 3 mL Prefilled Pen, Sample. Not for Resale., Rx only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, NDC 0169-28 — Novo Nordisk Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 897122, 897126, 1598268, 2735350 |
|---|---|
| SPL set ID of the quoted label | 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 |
| FDA labels (SPL) | 18 |
| FDA applications | NDA022341, NDA206321, 8 ANDA |
| Active ingredients (FDA) | LIRAGLUTIDE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Victoza, Novo Nordisk, effective October 14, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →